CB1 is the main Cannabinoid receptor in the brain but is also found in other tissues. CB1 is a G protein-coupled receptor which inhibits adenylyl cyclase and consequently reduces cAMP upon activation. This in turn regulates many second messenger pathways. 


cannabinoids have excellent therapeutic potential in epilepsy. In the brain, cannabinoids tend to keep neuronal activity wihtin acceptable boundaries.


pain is a very good target for therapeutic cannabinoids.


psoriasis is an auto-immune disease characterized by itchy skin lesions. psoriasis arises when the immune system mistakenly identifies skin cells as foreign matter and causes over-production of new skin cells.


OCD is an Anxiety disorder characterised by the obsessive urge for repetitive behaviour.


Huntington's disease is a genetic neurodegenerative disorder, marked by preferential degeneration of neurons in the basal ganglia (caudate and putamen) and accompanied by motor deficits, cognitive impairment and psychiatric symptoms.


Both plant cannabinoids and the endocannabinoid system have been implicated as risk factors in the development of depression as well as therapeutic targets to treat depression.


α2 receptors are classically known as adrenalin receptors. However, α2 receptors also bind CBG at very high affinity and are therefore also Cannabinoid receptors. The interaction between CBG and α2 receptors may be relevant in the treatment of pain and depression, but more research is required.


TRPV3 is one of the non-GPCR-coupled Cannabinoid receptors. TRPs are typically involved in pain sensation.


TRPM8 is involved in sensory perception.